David P Humphreys
Overview
Explore the profile of David P Humphreys including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
630
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hussain H, Ozanne A, Patel T, Vito D, Ellis M, Hinchliffe M, et al.
Biotechnol Bioeng
. 2024 Nov;
122(2):435-444.
PMID: 39587782
There are a number of new format antibody-inspired molecules with multiple antigen binding capabilities in development and clinical evaluation. Here, we describe the impact of the sequence and configuration of...
2.
Qureshi O, Sutton E, Bithell R, West S, Cutler R, McCluskey G, et al.
MAbs
. 2024 Jan;
16(1):2300155.
PMID: 38241085
Rozanolixizumab is a humanized anti-neonatal Fc receptor (FcRn) monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4) sub-class, currently in clinical development for the treatment of IgG autoantibody-driven diseases. This format...
3.
Dave E, Durrant O, Dhami N, Compson J, Broadbridge J, Archer S, et al.
MAbs
. 2023 Feb;
15(1):2160229.
PMID: 36788124
TrYbe® is an Fc-free therapeutic antibody format, capable of engaging up to three targets simultaneously, with long half-life conferred by albumin binding. This format is shown by small-angle X-ray scattering...
4.
Cable J, Saphire E, Hayday A, Wiltshire T, Mousa J, Humphreys D, et al.
Ann N Y Acad Sci
. 2022 Nov;
1519(1):153-166.
PMID: 36382536
Therapeutic antibodies have broad indications across diverse disease states, such as oncology, autoimmune diseases, and infectious diseases. New research continues to identify antibodies with therapeutic potential as well as methods...
5.
Hussain H, Patel T, Ozanne A, Vito D, Ellis M, Hinchliffe M, et al.
Biotechnol Bioeng
. 2021 Sep;
118(12):4815-4828.
PMID: 34585737
Monoclonal antibodies are the leading class of biopharmaceuticals in terms of numbers approved for therapeutic purposes. Antigen-binding fragments (Fab) are also used as biotherapeutics and used widely in research applications....
6.
Sopp J, Peters S, Rowley T, Oldham R, James S, Mockridge I, et al.
Commun Biol
. 2021 Sep;
4(1):1031.
PMID: 34475514
The majority of depleting monoclonal antibody (mAb) drugs elicit responses via Fc-FcγR and Fc-C1q interactions. Optimal C1q interaction is achieved through hexameric Fc:Fc interactions at the target cell surface. Herein...
7.
Bhatta P, Humphreys D
Antibodies (Basel)
. 2019 Sep;
7(3).
PMID: 31544885
Bispecific antibodies represent an emerging class of antibody drugs that are commonly generated by fusion of Fv or scFv antigen binding domains to IgG or Fab scaffolds. Fv- or scFv-mediated...
8.
Guerrero Montero I, Richards K, Jawara C, Browning D, Peswani A, Labrit M, et al.
Biotechnol Bioeng
. 2019 Aug;
116(12):3282-3291.
PMID: 31429928
Escherichia coli is a heavily used platform for the production of biotherapeutic and other high-value proteins, and a favored strategy is to export the protein of interest to the periplasm...
9.
Hussain K, Hargreaves C, Rowley T, Sopp J, Latham K, Bhatta P, et al.
Front Immunol
. 2019 Mar;
10:390.
PMID: 30899264
Monoclonal antibody (mAb) immunotherapy has transformed the treatment of allergy, autoimmunity, and cancer. The interaction of mAb with Fc gamma receptors (FcγR) is often critical for efficacy. The genes encoding...
10.
Dhami N, Trivedi D, Goodacre R, Mainwaring D, Humphreys D
Metabolomics
. 2019 Mar;
14(10):136.
PMID: 30830403
Introduction: Mammalian cells like Chinese hamster ovary (CHO) cells are routinely used for production of recombinant therapeutic proteins. Cells require a continuous supply of energy and nutrients to sustain high...